32P - Heterogeneity Analysis of DW MRI as a Biomarker for Prediction of Overall Survival and 6 Month PFS in GBM Patients
Manijeh Beigi, Tehran, Iran

33P - Somatic mutations of PIK3CA and AKT1 in Japanese breast cancer
Tatsunori Shimoi, Tokyo, Japan

34P - The expression and functional role of Cripto-1 in human colorectal cancer
Sato Jun, Sendai, Japan

35P - Clinical Significance of Expression of Cripto-1 in Patients of Squamous Cell Carcinoma of Oropharynx
Mallapattu Kumar, Chandigarh, India

36P - Clinical impact and carcinogenic mechanism of USP3 overexpression in gastric cancer
Kai-Yuan Lin, Tainan, Taiwan

37P - Expression pattern of cyclooxygenase-2 in carcinoma of cervix
Shahin Hameed, Cochin, India

38P - Mena INV: a prospective bio-marker of glioma under hypoxia
Mohita Bhagat, Delhi, India

39P - Impact of GSTP1 and ABCC4 Genes Polymorphism on Outbreak of Cyclophosphamide-based Chemotherapy-induced Grade 3/4 Febrile Neutropenia in Iranian Breast Cancer Patients
Maryam Mobaraki, Tehran, Iran

40P - Effect of ABCB1 and SLC22A16 Genes Polymorphism in Outbreak of Doxorubicin-based Chemotherapy-induced Grade 3/4 Febrile Neutropenia in Iranian Breast Cancer Patients
Abolfazl Faraji, Tehran, Iran

41P - Impact prognosis of cellular CD 69 expression with CD38 in Egyptian Chronic lymphocytic leukemia
Mohamed Elbaiomy, Dakahlia, Egypt

42P - Promoter hypermethylation of BRCA1, DAPK1 and RASSF1A is associated with increase mortality among breast cancer patients
Prasant Yadav, New Delhi, India

43P - Integrated analysis of genome-wide DNA methylation and gene expression profiles identifies potential novel biomarkers of rectal cancer
Guodong Li, Harbin, China

44P - Pharmacogenetic methods of personalization in medical treatment of colon cancer
Jamshid Ibragimov, Tashkent, Uzbekistan

45P - MIR-183 is frequently methylated and related to poor survival in human hepatocellular carcinoma
Sunadi Lukman Anwar, Yogyakarta, Indonesia

46P - Identification of novel biomarkers distinguishing pancreatic head cancer from distal cholangiocarcinoma discovered by proteomics analysis
Tsutomu Takenami, Sendai, Japan

47P - Loss-of-function PTPRD and PTPTD mutations predict bevacizumab resistance in metastatic colorectal cancer patients
Kien Thiam Tan, Taipei, Taiwan

48P - Inhibition of LAP2α can suppress breast cancer
Xiaofei Li, Hangzhou, China

49P - The role of circulating cell-free fluorescent assay to predict relapse receiving neoadjuvant chemotherapy
Kwonoh Park, Seoul, Republic of Korea

50P - Droplet digital PCR measurement in plasma cell-free DNA in patients
Hong-Fei Guo, Guangzhou, China

51P - Clinical Feasibility of EGFR M in Plasma Cell-free DNA of Lung Adenocarcinoma
Yang Yang, Nanjing, China

52P - Expression of CT antigens in P. Potential minimally-invasive Biomarker
Shivam Singh, Delhi, India

53P - Update results of a novel assay CpGs from sputum to screen patients
Takeshi Nagasaki, Okayama, Japan

54P - Circulating prostate-specific antigen nationally representative sample of men
Wahyu Wulansingh, London, UK

55P - CTC Count & Gene Expression P Herdee Giovane Luna, Quaxton City, Phil

56P - Single Circulating Tumor Cells RT Enrichment and Active Single Cell Select System
Yi Fang Lee, Singapore

57P - Inter-observer variability in program immunohistochemistry scoring in non-smokers
Alesha Thai, Heidelberg, Australia

58P - PD-L1 expression associated with in malignant pleural mesothelioma
Bella Nguyen, Canberra, Australia

59P - Characterization of PD-L1 expression in lung cancer patients with PTEN/PHC as screening
Xu-Chao Zhang, Guangzhou, China

60P - Expression of PD-L1 is associated with breast cancer: a meta-analysis
Minghui Zhang, Harbin, China

61P - Tumor-infiltrating lymphocytes/macrophage outcome in breast cancer
Yang-Seok Kim, Uijeongbu City, Republic of Korea

42P - Diagnosis of right upper lobar lymph node by mediastinal TLG
Hitoshi Demura, Nagoya, Japan